MedTrace Logo

Vascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation Lesions

NCT05200637 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-01-21

No results posted yet for this study

Summary

This study aims to compare vessel response and clinical outcomes of a biodegradable-polymer, ultra-thin strut, drug-eluting stent (Orsiro, Biotronik) and a durable-polymer, thin-strut, drug-eluting stent (Xience, Abbott) for the treatment of coronary bifurcation lesions with two-stent double-kissing crush technique. How the differences in stent platforms affect vessel healing process will be examined by optical coherence tomography.

Conditions

Interventions

DEVICE

Orsiro stent

Orsiro stent

DEVICE

Xience stent

Xience stent

DEVICE

Any drug-eluting stent

Any drug-eluting stent

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Ying-Chang Tung, MD · Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

  • Chi-Jen Chang, MD · Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

  • Chia-Pin Lin, MD · Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200637 on ClinicalTrials.gov